Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s blockbuster Wegovy medicine to treat a serious fatty liver disease. Shares in Novo Nordisk rose as much as 5% in early European trading Monday,

Novo Nordisk A/S's Wegovy received Food and Drug Administration approval to treat metabolic-associated steatohepatitis in adults with moderate to advanced scar tissue in the liver.